Annexon, INC 8-K filings

Annexon, Inc. announced second quarter 2026 financial results, business updates including expansion of its Vonaprument Phase 3 program for geographic atrophy, and a $200 million credit facility.

Annexon's FORWARD study shows rapid, positive clinical responses in all Guillain-Barré Syndrome patients treated with tanruprubart within one week, reinforcing its potential as a first-in-class targeted therapy.

Annexon, Inc. has entered into a strategic credit facility agreement with Oxford Finance LLC for up to $200 million to support its biopharmaceutical programs.

Annexon, Inc. announced the results of its 2026 Annual Meeting, with shareholders electing two Class III directors, ratifying KPMG as auditors, approving executive compensation, and increasing authorized common stock.

Annexon reported higher FY25 R&D spend, an EU MAA filing for GBS, $238.3M in cash with runway into H2 2027, and expects pivotal GA data in Q4 2026.

Annexon, Inc. updated its corporate presentation, highlighting significant progress in its late-stage neuroinflammatory disease pipeline, including Vonaprument for dry AMD with GA and Tanruprubart for Guillain-Barré Syndrome.

Annexon, Inc. outlines its 2026 strategic priorities and key milestones, including regulatory filings and pivotal trial data for its lead neuroinflammatory programs.

Annexon, Inc. successfully closed its public offering, raising approximately $86.25 million in gross proceeds through the sale of common stock and pre-funded warrants, including the full exercise of the underwriters' option.

Annexon, Inc. announced its third quarter 2025 financial results and provided updates on its late-stage neuroinflammation pipeline, including GBS and GA programs.

Annexon, Inc. announced its second quarter 2025 financial results and highlighted significant progress across its late-stage clinical pipeline, including anticipated regulatory submissions and trial data readouts.

Annexon, Inc. has amended its 2022 common stock purchase warrants, extending their term by one year to June 30, 2026, and requiring cash-only exercise, which could generate up to $39.9 million in proceeds.

Annexon, Inc. announced the successful election of two Class II directors, the ratification of KPMG LLP as its independent auditor, and the advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Annexon reports first quarter 2025 financial results, highlighting portfolio progress and key anticipated milestones, including an upcoming FDA meeting for tanruprubart and accelerated enrollment in the Phase 3 ARCHER II trial.

Annexon announces promising Phase 3 data for ANX005 in GBS, a groundbreaking registration path for ANX007 in dry AMD with GA, and progress in the ANX1502 trial for autoimmune conditions, alongside a strong financial position.

Annexon, Inc. has released its 2025 outlook, emphasizing progress and upcoming milestones for its key drug programs targeting neuroinflammatory diseases.

Annexon, Inc. has appointed William Jones, a seasoned commercial executive, to its board of directors to support the company's commercialization efforts.

Annexon's ANX005 shows faster and greater improvement in muscle strength and disability compared to standard treatments in a real-world study of Guillain-Barr Syndrome patients.

Annexon announced its third quarter 2024 financial results, highlighted progress in its clinical programs, and provided key anticipated milestones.

Annexon's ANX007 demonstrated enhanced vision protection and greater preservation of photoreceptor cells in a subpopulation of dry age-related macular degeneration patients with less advanced disease in a Phase 2 study.

Annexon announced positive results from its Phase 3 trial for ANX005 in GBS, initiated dosing in the ARCHER II trial for ANX007 in GA, and completed a bridging study for oral inhibitor ANX1502, while also reporting a strong cash position.

Annexon has begun patient dosing in its Phase 3 ARCHER II trial for ANX007, a potential treatment for geographic atrophy, while also reporting positive data from its Phase 2 ARCHER trial.

Annexon reports positive Phase 3 trial results for ANX005, showing faster and more complete recovery in Guillain-Barr Syndrome patients compared to placebo.

Annexon, Inc. held its 2024 Annual Meeting of Stockholders on June 5, 2024, where directors were elected and the company's auditor was ratified.

Annexon, a biopharmaceutical company, has announced the pricing of a $125 million public offering of common stock and pre-funded warrants to advance its clinical platform.

Annexon's ANX005 demonstrated a statistically significant 2.4-fold improvement on the GBS-disability scale in a Phase 3 trial for Guillain-Barré syndrome.

Annexon announced first quarter 2024 financial results and highlighted progress across its clinical programs, including upcoming pivotal data for ANX005 in Guillain-Barr Syndrome and initiation of a Phase 3 trial for ANX007 in Geographic Atrophy.

Annexon presented new clinical and preclinical data at the ARVO 2024 Annual Meeting demonstrating the neuroprotective effects of ANX007 in geographic atrophy, including significant protection against vision loss and preservation of key retinal structures.

Annexon announced its fourth quarter and year-end 2023 financial results, highlighting progress in its clinical programs and anticipating key data readouts and trial initiations in 2024.

Annexon's R&D Day presentation focused on their novel therapeutic approach for Guillain-Barré Syndrome (GBS) and provided an update on their Phase 3 clinical trial.